Mode
Text Size
Log in / Sign up

PLEKHA6 variants identified in 24 patients with idiopathic hypogonadotropic hypogonadism across two cohorts

PLEKHA6 variants identified in 24 patients with idiopathic hypogonadotropic hypogonadism across two …
Photo by Navy Medicine / Unsplash
Key Takeaway
Note that PLEKHA6 variants identified in 1.3% of an IHH cohort may represent a novel genetic cause.

This cohort study analyzed 1,822 patients with idiopathic hypogonadotropic hypogonadism (IHH) across two independent cohorts. The primary objective was the identification of PLEKHA6 variants and their segregation with the disease. No comparator group was utilized as this was a discovery-focused genetic analysis.

The study identified 18 distinct PLEKHA6 variants in 24 patients from 20 unrelated families, accounting for 1.3% of the total cohort. These variants segregated with disease under both autosomal recessive and autosomal dominant inheritance patterns, with variable penetrance observed in the dominant cases.

Secondary analyses assessed PLEKHA6 expression in the postmortem human hypothalamus and kisspeptin secretion in cell-based assays. PLEKHA6 was robustly expressed in the hypothalamus and showed clear colocalization with neurokinin B. Patient variants significantly impaired kisspeptin secretion in these assays. PLEKHA6 is a novel IHH gene and the first reported regulator of kisspeptin secretion from the kisspeptin-neurokinin B-dynorphin (KNDy) neurons.

Safety data, adverse events, and discontinuations were not reported as this was a genetic discovery study. Limitations include the observational nature of the cohort design and the fact that causality is inferred from segregation rather than randomized intervention. The practice relevance lies in expanding the genetic differential for IHH, though clinical application requires further validation.

Study Details

Study typeCohort
Sample sizen = 1,822
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
PurposeIdiopathic hypogonadotropic hypogonadism (IHH) is characterized by impaired reproductive maturation, and approximately half of all cases lack an identified genetic cause. We investigated the genetic basis of IHH in two large cohorts to identify novel disease-causing genes. MethodsWe analyzed exome and genome sequencing data from 1,822 patients with IHH from two independent cohorts. Rare variants were filtered using pedigree-informed inheritance models. PLEKHA6 expression in the postmortem human hypothalamus were tested at the mRNA and protein level. Functional studies assessed kisspeptin secretion in cell-based assays. ResultsWe identified 18 distinct PLEKHA6 variants in 24 patients from 20 unrelated families (1.3% of cohort). Variants segregated with disease under autosomal recessive and autosomal dominant (with variable penetrance) inheritance patterns. PLEKHA6 was robustly expressed in the hypothalamus and showed clear colocalization with neurokinin B, which served as the marker for the GnRH pulse generator. Functional studies demonstrated that patient variants significantly impaired kisspeptin secretion. ConclusionPLEKHA6 is a novel IHH gene and the first reported regulator of kisspeptin secretion from the kisspeptin-neurokinin B-dynorphin (KNDy) neurons, which have recently been established as the GnRH pulse generator. These findings establish impaired kisspeptin release as a new disease mechanism in IHH and highlight the critical role of neuropeptide trafficking in reproductive function.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.